AstraZeneca reports HICKORY results for AstraZeneca stock

AstraZeneca (ISIN GB0009895292) reported HICKORY Phase III results on October 11, 2026, with efzimfotase alfa showing a 17.05-meter improvement versus placebo in the six-minute walk test. The result missed statistical significance, making the data important for the company's rare-disease pipeline and regulatory case.

HICKORY balances benefit and risk

According to AstraZeneca, 45.20 percent of treated patients reached the minimum clinically important difference in the walk test, compared with 30.00 percent for placebo. The company also reported a 5.74-point improvement in the FACIT-Fatigue measure, while stating that the primary endpoint did not achieve statistical significance.

The result follows AstraZeneca's USD 2.0 billion equity investment in Summit Therapeutics. AstraZeneca said on October 5, 2026, that the investment would accelerate development of ivonescimab, a bispecific antibody targeting PD-1 and VEGF. The transaction gives AstraZeneca rights equivalent to approximately 12.00 percent of Summit's outstanding common stock, according to the company's September 28, 2026 announcement.

What does the pipeline mean?

The two announcements show the different evidence profiles behind AstraZeneca's growth strategy. The Summit transaction adds oncology exposure through a capital commitment, while HICKORY provides supportive secondary results alongside a primary endpoint that missed statistical significance.

Three dated pipeline milestones

On September 28, 2026, AstraZeneca announced the USD 2.0 billion Summit investment and clinical collaboration. On October 5, 2026, the company completed that investment, as reported in its release. On October 11, 2026, AstraZeneca published the 17.05-meter HICKORY result and the 45.20 percent versus 30.00 percent response comparison.

Upcoming dates for investors

AstraZeneca's investor-relations calendar lists an ESMO management event in Madrid on October 26, 2026, followed by its nine-month and third-quarter 2026 results on October 30, 2026. Both dates appear on the company's investor-relations page.

Pipeline breadth meets valuation

AstraZeneca's market capitalization was USD 251.3 billion as of October 14, 2026, while the company operates across oncology, rare disease and biopharmaceuticals. For investors, the next reporting date offers the clearest scheduled test of whether pipeline investment is translating into broader financial momentum.

Stock price in German trading

AstraZeneca stock was trading at EUR 147.03 at Lang & Schwarz on October 15, 2026 at 9:44 a.m. CEST. The quote was in the regular Xetra trading phase.

The further course of trading is shown by the continuously updated real-time quote of AstraZeneca stock.

Market context: Market report FTSE 100.

More news and analyses on AstraZeneca stock